BioSpace News Archive

Nexcella, Inc. (“Nexcella”, “Company”, “We” or “Us”), today announced that effective today, Henry A. McKinnell, Jr, Ph.D., former Chairman and Chief Executive Officer of Pfizer Inc., has been appointed to the Company’s Board of Directors.

Pluristyx and panCELLa, a merged biotechnology company with offices in Seattle, WA and Toronto, Ontario, CA, are excited to announce their acceptance as an Industry Resource Partner with the California Institute for Regenerative Medicine.

Range Biotechnologies has received $5.2 million in Seed funding led by TechBio-focused ARTIS Ventures, with additional participation from Pear VC, Page One Ventures, Civilization Ventures, Pillar, Four Cities Capital, Hawktail, and others.

AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications, announced that chairman and CEO Dr. Hans Keirstead will deliver a keynote at the Digital Innovation Summit, taking place June 12-13 in St. Andrews, New Brunswick, Canada.

Ausper Biopharma Co., Ltd. And AusperBio Therapeutic, Inc. (Together AusperBio), a clinical-stage biotechnology company, today announces the presentation of two posters, SAT-173 and SAT-178, at the annual meeting of the European Association for the Study of the Liver, EASL™ Congress 2023, taking place in Vienna from June 21-24.

BIOTRONIK, a leader in implantable medical device technology, today announced the first global implantation of its BIOMONITOR IV implantable cardiac monitor (ICM).

Disc Medicine, Inc. announced that it has commenced an underwritten public offering of $100 million of shares of its common stock and, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock.

Revelation Biosciences Inc. announced that the Company has adjourned its 2023 Annual Meeting of Stockholders originally scheduled to be held on June 9, 2023, to July 7, 2023, at 1:00 p.m., Eastern Time, or at such other time or such other date to which the meeting may be adjourned.

KalVista Pharmaceuticals, Inc. announced that it presented data on sebetralstat and quality of life issues experienced by people living with hereditary angioedema at the 2023 Meeting of the European Academy of Allergy and Clinical Immunology in Hamburg, Germany.

Genelux Corporation announced a private placement for 900,000 shares of the Company’s common stock at a purchase price of $20.00 per share, for gross proceeds of approximately $18 million, before deducting offering expenses payable by Genelux.